Ondine Biomedical Inc. NPV (CDI) (OBI)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 8.13p
   
  • Change Today:
      0.000p
  • 52 Week High: 10.50p
  • 52 Week Low: 5.13p
  • Currency: UK Pounds
  • Shares Issued: 394.08m
  • Volume: 10,000
  • Market Cap: £32.02m
  • Beta: 0.89

Ondine technology 'highly effective' against MRSA isolates

By Josh White

Date: Wednesday 19 Oct 2022

LONDON (ShareCast) - (Sharecast News) - Canada-based life sciences company Ondine Biomedical announced new research on Wednesday, showing that its photodisinfection technology was "highly effective" against clinical MRSA isolates that exhibited multi-drug resistance.
The AIM-traded firm said that, with more than a quarter of people colonised with staphylococcus aureus in the nose and some of those carrying the MRSA type, there remained an unmet need for new therapies.

Few new antibiotics were under development, and alternative means of killing drug-resistant infections needed to be found, with light-activated compounds providing a possible answer.

The company said the new research was conducted using 100 recent multidrug-resistant staphylococcus aureus MRSA clinical isolates obtained from patients presenting to a large tertiary care hospital in Vancouver.

Each isolate was selected for resistance to one or more major classes of antibiotics in widespread use today, and then subjected to 'Steriwave' photodisinfection in vitro.

The study found that the photodisinfection treatment eliminated more than 99.9% of each isolate in 60 seconds, irrespective of the isolate's antibiotic resistance.

"Antibiotic resistance is one of the most dangerous developments in clinical medicine," said the company's vice-president of medical and clinical affairs, Jason Hickok.

"Over 200 Americans and 78 Britons die each day from an untreatable hospital-acquired infection, and hundreds of patients more suffer from comorbidities and disfigurements of lifesaving revision surgeries and associated treatment."

Hickok said the loss of antibiotics could see the return of a way of life last seen almost a century ago, where a scratched knee or a minor burn could prove lethal.

"This research demonstrates the power of Steriwave photodisinfection, a modern photonic solution to topical disinfection without using antibiotics, without engendering resistance, and without causing pain or side effects to the patient."

At 1305 BST, shares in Ondine Biomedical were down 0.89% at 26.76p.

Reporting by Josh White at Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OBI Market Data

Currency UK Pounds
Share Price 8.13p
Change Today 0.000p
% Change 0.00 %
52 Week High 10.50p
52 Week Low 5.13p
Volume 10,000
Shares Issued 394.08m
Market Cap £32.02m
Beta 0.89

OBI Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
70.64% below the market average70.64% below the market average70.64% below the market average70.64% below the market average70.64% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
19.04% below the market average19.04% below the market average19.04% below the market average19.04% below the market average19.04% below the market average
14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average
Income Not Available
Growth
29.79% above the market average29.79% above the market average29.79% above the market average29.79% above the market average29.79% above the market average
41.18% above the sector average41.18% above the sector average41.18% above the sector average41.18% above the sector average41.18% above the sector average

OBI Dividends

No dividends found

Trades for 21-Nov-2024

Time Volume / Share Price
15:33 10,000 @ 8.00p

OBI Key Personnel

Chair Jean Charest
CEO Carolyn Cross

Top of Page